Sector
PharmaceuticalsOpen
₹19.53Prev. Close
₹19.24Turnover(Lac.)
₹254.18Day's High
₹19.53Day's Low
₹19.152 Week's High
₹27.952 Week's Low
₹12.31Book Value
₹3.57Face Value
₹1Mkt Cap (₹ Cr.)
1,807.62P/E
37.04EPS
0.52Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 94 | 94 | 91.29 | 88.75 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 192.45 | 162.01 | 130.94 | 98.84 |
Net Worth | 286.45 | 256.01 | 222.23 | 187.59 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 244.8 | 205.51 | 158.63 | 184.82 |
yoy growth (%) | 19.12 | 29.55 | -14.17 | 0.5 |
Raw materials | -161.46 | -151.62 | -108.94 | -128.11 |
As % of sales | 65.95 | 73.77 | 68.68 | 69.31 |
Employee costs | -19.66 | -16.29 | -15.04 | -14.49 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 40.67 | 17.34 | 12.11 | 16 |
Depreciation | -4.03 | -4.06 | -3.72 | -3.12 |
Tax paid | -11.53 | -3.03 | -3.36 | -5.34 |
Working capital | 84.97 | 9.2 | 8.52 | 11.14 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.12 | 29.55 | -14.17 | 0.5 |
Op profit growth | 127.39 | 42.55 | -28.62 | -1.5 |
EBIT growth | 130.01 | 43.76 | -24.08 | 0.23 |
Net profit growth | 104.66 | 64.83 | -18.82 | 2.86 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2017 |
---|---|---|---|---|---|
Gross Sales | 465.01 | 263.39 | 224.25 | 219.66 | 182.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 465.01 | 263.39 | 224.25 | 219.66 | 182.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 17.44 | 13.53 | 14.61 | 12.02 | 4.86 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
Kedarmal Bankda
Managing Director
Vijay Shankarlal Bankda
Whole-time Director
Rinki Bankda
Independent Director
Ruchi Jindal
Company Sec. & Compli. Officer
Vaishali Agrawal
Independent Director
Ritesh Kumar Lunkad
Independent Director
Ankit Jain
7 Niraj Indl Estate Andheri(E),
Off Mahakali Caves Rd,
Maharashtra - 400093
Tel: 91-22-30887744
Website: http://www.syncomformulations.com
Email: finance@sfil.in; sfil87@syncomformulations.com
Plot No. 60,
Electronic Complex, Pardeshipura,
Indore - 452010
Tel: 91-0731-3198601/3198
Website: www.ankitonline.org
Email: ankit_4321@yahoo.com
Summary
Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.92. The Company in the Indian Pharmaceutical Industry represen...
Read More
Reports by Syncom Formulations (India) Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.